WEST CHESTER, Ohio, Feb. 5 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation products, will release its financial results for the fourth quarter and full year ended December 31, 2007 on Thursday, February 14, 2008.
AtriCure will host a conference call at 10:00 a.m. ET on Thursday,
February 14, 2008 to discuss fourth quarter and full year 2007 results. A
live web cast of the conference call will be available online from the
investor relations page of AtriCure's corporate web site at
Pre-registration is available for this call at the following URL:
Pre-registering is not mandatory but is recommended as it will provide you immediate entry into the call and will facilitate the timely start of the conference. Pre-registration only takes a few moments and you may pre-register at any time, including up to and after the call start time. Alternatively, if you prefer being placed into the call by an operator, please call (888) 713- 4214 for domestic callers and (617) 213-4866 for international callers at least 15 minutes prior to the call start time and use reservation number 25413911.
The web cast will remain available on AtriCure's web site through March 15, 2008. A telephonic replay of the call will also be available until March 15, 2008. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. Please use reservation code 60682842.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation system as a treatment alternative during open-heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, medical journals and leading cardiothoracic surgeons have described the AtriCure Isolator(R) system as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 2.5 million Americans and predisposes them to a five-fold increased risk of stroke.
The FDA has cleared the AtriCure Isolator(R) bipolar ablation system,
including the new Isolator Synergy(TM) ablation clamps and the AtriCure
multifunctional bipolar Pen, for the ablation, or destruction, of cardiac
tissues during surgical procedures. Additionally, the FDA has cleared the
AtriCure Pen for temporary pacing, sensing, stimulating and recording
during the evaluation of cardiac arrhythmias. To date, the FDA has not
cleared or approved AtriCure's products for the treatment of AF. AtriCure's
left atrial appendage clip system has not been approved for commercial use.
It is currently being used in clinical evaluations in Europe.
Julie A. Piton
Vice President and Chief Financial Officer
|SOURCE AtriCure, Inc.|
Copyright©2008 PR Newswire.
All rights reserved